Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

Lotte Bjerre Knudsen lives comfortably in this pleasant, but not showy, £900,000 apartment in central Copenhagen with her ...

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a ...

Viking is developing what might be a game-changing medication in the segment. Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered better-than-expected non-farm payrolls last month while digesting more ...

Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the ...

A decision is expected in the fourth quarter of 2025.

Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...